Generation and Characterization of a New Preclinical Mouse Model of EGFR-Driven Lung Cancer with MET-Induced Osimertinib Resistance

Generation and Characterization of a New Preclinical Mouse Model of EGFR-Driven Lung Cancer with MET-Induced Osimertinib Resistance

Despite the introduction of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) to treat advanced lung cancer harboring EGFR-activating mutations, the prognosis remains unfavorable because of intrinsic and/or acquired resistance. We generated a new state-of-the-art mouse strain...

Full description

Bibliographic Details
Main Authors: Maicol Mancini, Quentin-Dominique Thomas, Sylvia Bourdel, Laura Papon, Emilie Bousquet, Prisca Jalta, Silvia La Monica, Camille Travert, Roberta Alfieri, Xavier Quantin, Marta Cañamero, Antonio Maraver
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Cancers
Subjects:
lung cancer
EGFR
MET
TKI
preclinical mouse models
Online Access:https://www.mdpi.com/2072-6694/13/14/3441

Internet

https://www.mdpi.com/2072-6694/13/14/3441

Similar Items